(NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced results from a Phase I-II clinical study at Skåne University Hospital in Lund, Sweden evaluating the ClearPoint Prism Neuro Laser Therapy System's safety, feasibility, and efficacy. The study cohort comprised fourteen patients ages 18-80years with primary and recurrent glioblastoma and grade 4 astrocytoma, tumors which are among the most challenging to t ...

The clearly established history across global regulatory bodies is expected to de-risk BioPharma partners' pathways towards achieving global scale and standardization. SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 6, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced several expanded regulatory approvals for product use in Canada, Hong Kong, and Taiwan. ...

Key Takeaways CLPT introduced a robotic system integrating its neuro-navigation software with KUKA's arm.CLPT's platform targets biopharma partners launching complex brain-delivered cell and gene therapies.Collaborations and software focus reduce risk, speed timelines, and position CLPT for long-term growth.ClearPoint Neuro (CLPT) recently unveiled the development of its proprietary Robotic Neuro-Navigation System, a move that positions the company to contribute to robotics, neurosurgery, and advanced drug ...

At 7:50 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading highe ...

ClearPoint Neuro's (NASDAQ: CLPT ) share price recently surged on the back of uniQure's ( QURE ) extremely strong Huntington's data. While the financial impact of AMT-130 should be meaningful, the data is more important as confirmatory evidence of the strength of ClearPoint’sRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can b ...

ClearPoint Neuro's (NASDAQ: CLPT ) share price recently surged on the back of uniQure's ( QURE ) extremely strong Huntington's data. While the financial impact of AMT-130 should be meaningful, the data is more important as confirmatory evidence of the strength of ClearPoint’sRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can b ...

New Product Category Will Enable Added Flexibility to Support Commercial Launches of Cell and Gene Therapy SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 1, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today formally announced the development and demonstration of the Company's proprietary Robotic Neuro-Navigation System. This new product category will enable the ClearPoint Neuro ...

ClearPoint Neuro, Inc. (NASDAQ: CLPT ), caught my eye today. Its stock has rallied over 100% in just the last few days, and yet, there is no official news/press release from the company. Upon some research, I soon discovered thatAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for ...

Core Insights - ClearPoint Neuro, Inc. (NASDAQ: CLPT) has experienced a stock price increase of over 100% in a short period without any official news or press release from the company [1] Group 1 - The significant stock rally of ClearPoint Neuro has drawn attention, indicating potential investor interest or market speculation [1] - The lack of official announcements from the company raises questions about the reasons behind the stock price surge [1] - Further research is needed to understand the underlying factors contributing to the stock's performance [1]

Core Insights - ClearPoint Neuro, Inc. announced the appointment of Dr. Paul Larson as Chief Medical Officer starting January 2026 [1] - Dr. Larson has a significant history with ClearPoint Neuro, having served as an advisor focused on education and product development in cell and gene therapy delivery [1] Company Developments - The company is enhancing its leadership team with the addition of Dr. Larson, which may strengthen its capabilities in the medical device and therapy sectors [1] - Dr. Larson's expertise is expected to support ClearPoint Neuro's ongoing efforts in advancing cell and gene therapy technologies [1]